Viral Vector Manufacturing Market 2025–2029: Tracking 20.5% CAGR Toward $17.42 Billion in Revenue

Uncover key drivers, emerging technologies, and competitive movements shaping the viral vector manufacturing market from 2025–2034 with trusted insights from The Business Research Company

How Will The Viral Vector Manufacturing Market Size Evolve Between Now And 2029?

The viral vector manufacturing market has observed substantial growth in its size over recent years. It is expected to expand from $6.93 billion in 2024 to $8.26 billion in 2025, achieving a compound annual growth rate (CAGR) of 19.1%. This historic expansion is largely attributable to factors such as an expanding pipeline of gene therapies, successful clinical outcomes and subsequent approvals, increased investment within the biopharmaceutical sector, and a higher prevalence of genetic disorders.

The viral vector manufacturing market size is projected to experience substantial expansion in the coming years. Its valuation is set to reach $17.42 billion by 2029, demonstrating a compound annual growth rate (CAGR) of 20.5%. This anticipated growth is driven by factors such as the broadening applications within oncology, international partnerships in gene therapy research, the increasing use of viral vectors in vaccine development, and ongoing clinical trials and subsequent commercialization. Key trends anticipated during this period encompass technological innovations in vector production, the emergence of next-generation vectors, requirements for regulatory compliance and standardization, various collaborations and partnerships, and the worldwide expansion of manufacturing facilities.

Access A Free Sample Of The Report:

https://www.thebusinessresearchcompany.com/sample.aspx?id=12398&type=smp

Which Key Drivers Are Powering Growth In The Viral Vector Manufacturing Market?

The rising incidence of cancer and infectious diseases is anticipated to boost the expansion of the viral vector manufacturing market in the future. An infectious disease is defined as an ailment caused by a virus or its harmful secretions, transmitted to a vulnerable host through interaction with an infected individual, animal, or object. Cancer encompasses a wide variety of conditions that can emerge in any bodily organ or tissue when abnormal cells proliferate uncontrollably, extend beyond their normal limits to infiltrate adjacent organs, and metastasize to distant organs. Viral vectors are utilized to generate tumor antigens, which are proteins found on tumor cells, thereby stimulating the body’s immune system to combat cancer. During pre-clinical and clinical investigations, viral vectors have functioned as vaccines to protect against numerous infectious diseases. As an illustration, in July 2024, data from the Australian Institute of Health and Welfare, an Australia-based government agency, indicated that in Australia, cancer diagnoses climbed from 160,570 in 2022 to 164,694 in 2023, showing a significant increase within the year. This rising pattern underscores the expanding incidence of cancer throughout the nation. Moreover, for example, in August 2024, statistics released by the UK Health Security Agency, a UK-based executive agency, revealed that in England, the UK Health Security Agency (UKHSA) recorded 368 measles cases in 2023, representing an almost sevenfold jump from the 53 cases documented in 2022, with the West Midlands and London making up 44% and 33% of these cases, respectively. Consequently, the expanding occurrence of cancer and infectious diseases is fueling the development of the viral vector manufacturing market.

How Is The Global Viral Vector Manufacturing Market Structured By Key Segments?

The viral vector manufacturing market covered in this report is segmented –

1) By Type: Adenoviral Vectors, Adeno-Associated Viral Vectors, Lentiviral Vectors, Retroviral Vectors, Other Types

2) By Disease: Cancer, Genetic Disorders, Infectious Diseases, Other Diseases

3) By Workflow: Upstream Processing, Downstream Processing

4) By Application: Gene And Cell Therapy Development, Vaccine Development, Biopharmaceutical And Pharmaceutical Discovery, Biomedical Research

5) By End-User: Research Organizations, Biotech And Pharmaceutical Companies, Others End Users

Subsegments:

1) By Adenoviral Vectors: Serotype 5, Serotype 2, Serotype 26

2) By Adeno-Associated Viral Vectors: AAV2, AAV5, AAV8, AAV9, Others

3) By Lentiviral Vectors: HIV-1-Based Lentiviral Vectors, SIV-Based Lentiviral Vectors, Others

4) By Retroviral Vectors: Moloney Murine Leukemia Virus (MoMLV), Gammaretroviral Vectors, Others

5) By Other Types: Sendai Viral Vectors, Vesicular Stomatitis Virus (VSV)-Based Vectors, Measles Virus Vectors, Others

What Future-Focused Trends Are Anticipated In The Viral Vector Manufacturing Market?

Product innovation is a significant trend gaining popularity in the viral vector manufacturing market. Major companies operating in this market are introducing product innovations to sustain their position. For instance, in August 2022, Merck KGaA, a Germany-based science and technology company, launched the VirusExpress 293 Adeno-Associated Virus (AAV) Production Platform. This positions them as one of the first Contract development and manufacturing organizations and technology creators to offer a comprehensive viral vector manufacturing package, including AAV, Lentiviral, CDMO, CTO, and process development. This innovative platform enables biopharmaceutical businesses to reduce the time and expense of process development, thereby accelerating the timeline to clinical manufacture.

Which Companies Hold A Competitive Edge In The Viral Vector Manufacturing Market?

Major companies operating in the viral vector manufacturing market include Sanofi S.A., Thermo Fisher Scientific Inc., Merck Group, FUJIFILM Holdings Corporation, Lonza Group, Catalent Inc., Sartorius AG, Charles River Laboratories International Inc., AGC Biologics, Ultragenyx Pharmaceutical Inc., Novasep Holding SAS, Aldevron LLC, Oxford Biomedica plc, LakePharma Inc., Voyager Therapeutics Inc., Mustang Bio Inc., Regenxbio Inc., VGXI Inc., BioNTech IMFS GmbH, FinVector Oy, Vigene Biosciences Inc., Univercells Technologies, Sirion-Biotech GmbH, Cevec Pharmaceuticals GmbH, Batavia Biosciences BV.

Download The Full Report Here:

https://www.thebusinessresearchcompany.com/report/viral-vector-manufacturing-global-market-report

Which Region Is Expected To Lead The Viral Vector Manufacturing Market In The Next Few Years?

North America was the largest region in the viral vector manufacturing market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the viral vector manufacturing market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa

Get A Report Customized For You Here:

https://www.thebusinessresearchcompany.com/customise?id=12398&type=smp

Browse Through More Reports Similar to the Global Viral Vector Manufacturing Market 2025, By The Business Research Company

Viral Vectors And Plasmid Dna Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/viral-vectors-and-plasmid-dna-global-market-report

Vector Control Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/vector-control-global-market-report

Bacterial And Plasmid Vector Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/bacterial-and-plasmid-vector-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795